Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Idarubicin · Idamycin, Idamycin Pfs

Small molecule · Cytotoxic, directed at DNA and topoisomerase II (TOP2A) · developed by Pfizer

Approved FDA, Sep 1990
2 Registered trials

What is Idarubicin?

Idarubicin is a semisynthetic anthracycline, a 4-demethoxy analogue of daunorubicin, that intercalates into DNA and inhibits topoisomerase II, interfering with DNA replication, RNA transcription and protein synthesis. It is studied in acute myeloid leukemia (AML), including AML with NPM1 mutation and KMT2A rearrangement.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Idamycin, Idamycin Pfs, Ara-C±IDA
Drug type
Small molecule
Targets
DNA, topoisomerase II (TOP2A)
Mechanism
Cytotoxic, directed at DNA and topoisomerase II (TOP2A)
Pathways
DNA replication inhibition, RNA transcription inhibition, protein synthesis inhibition, free radical-mediated DNA damage
Therapy area
Oncology
Developer
Pfizer
In trials of
KURA, SBFM
FDA status
Approved as Idamycin, Idamycin Pfs (September 27, 1990), NDA050661 · FDA label
UNII
ZRP63D75JW

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 15, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05586074 Phase 3 Leukemia, Acute Myeloid (AML) Recruiting SBFM
NCT06001788 Phase 1 AML Recruiting KURA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute LeukemiaAcute Myeloid LeukemiaAMLAML With Mutated NPM1Hematologic MalignancyKMT2ArLeukemiaLeukemia, Acute Myeloid (AML)Leukemia, MyeloidLeukemia, Myeloid, AcuteMLL RearrangementNeoplasms by Histologic TypeNPM1 Mutation

Other drugs acting on TOP2A

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.